[Clinical trial of the antibacterial combination sulfamoxole/trimethoprim (CN 3123)/Third communication: Clinical results of a field trial with CN 3123 in bronchopulmonary and ENT (ear/nose/throat) infections (author's transl)]

Abstract

The following conclusions emerged from an analysis of the therapeutic results documented during the clinical trial of N1-(4,5-dimethyl-2-oxazolyl)-sulfanilamide (sulfamoxole) and 2,4-diamino)-5-(3,4,5-trimethoxy-benzyl)-pyrimidine (trimethoprim) (CN 3123, Nevin, Supristol) in bacterial infections of the respiratory tract and ENT organs: 1. In bacterial infections of the bronchopulmonary system, the antibacterial activity of CN 3123 was demonstrated in 94% of the patients, in that 75% of patients were cured and there was a definite improvement in 19%. 2. In bacterial infections of the ENT organs, the antibacterial activity of CN 3123 was demonstrated clinically in 95% of the patients, in that 89% of the patients were cured and there was a definite improvement in 6%. 3. The clinical assessment of the activity of CN 3123 correlates closely with the results of bacteriological checks.